Israel-Medical-Healthcare

[genisi]

Rosetta Genomics Announces Expansion of its Research Facility

Tue Jul 17 05:45:42 2007

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 17 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq: ROSG), a leading microRNA company, announced today the expansion of its Israeli research facility. The company is adding the new laboratories to its state-of-the-art facilities in order to meet its research and development needs for its microRNA-based diagnostic programs. The company expects to grow to approximately 70 employees by the end of the year.

"This expansion will enable us to advance new development programs, and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," said Amir Avniel, Rosetta Genomics' Chief Executive Officer. "Our proprietary discovery platform is capable of utilizing over twelve thousand predicted and validated microRNAs, including over 1000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring (endogenous), molecule that initiates the RNAi process. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human illnesses. In addition, microRNAs have been shown to have different expression levels in certain pathological versus normal tissues. As a result, these differences may provide the basis for a novel diagnostic strategy for a wide range of diseases.

About Rosetta Genomics

Rosetta Genomics (NASDAQ:ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases. For more information please visit: http://www.rosettagenomics.com

http://www.omniomix.com/inthenews.php?id=80612